Drug Trial Radar · NCT06524414
A Study to Learn About How a New Pneumococcal Vaccine Works in Infants
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
605
Actual
Start
Jul 25, 2024
Primary completion
Mar 4, 2027
Study completion Mar 4, 2027
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jul 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 42 days, up to 98 days
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs in infants when compared to the pneumococcal vaccines that are currently in use, 20vPnC (Prevnar 20®) or another licensed pneumococcal vaccine. To ensure that the new vaccine (PG4) stays stable, it is placed in a liquid mixture of sterile water and other substances (a solution). This study will also test if there is a difference in the safety and immune effects of the new pneumococcal vaccine when it is one type of solution compared to when it is in a different type of solution. The immune response is how the body's cells; tissues and organs work together to protect the body from infection. Blood samples will be used to measure the amount of antibodies produced after the vaccination. Antibodies are proteins that protect you when an unwanted germ enters the body. This will help understand how well the new pneumococcal vaccine works. This vaccine can possibly provide protection against pneumococcal disease. Pneumococcal disease includes a variety of infections caused by a specific germ, Streptococcus pneumoniae. This study is seeking participants who are: * male or female infants who are 2 months of age, * infants born at 36 weeks (about 8 and a half months) of pregnancy or later; and, * said to be healthy by the study doctor There are four groups in this study. All participants will be assigned to one of the four groups. All study vaccines will be given as a single shot into the left thigh muscle. Participants in the three groups will have 3 blood samples collected during the 1 and a half years they are in the study. The first 400 participants who enter the study will be assigned to either Group 1 or Group 2. Half the participants in Group 1 and half the participants in Group 2 will receive 4 doses at 2, 4, 6, and 12 to 15 months of age of PG4 mixed in the first solution. The other half of the participants in Groups 1 and 2 will receive 4 doses of 20vPnC (Prevnar 20®) at 2, 4, 6, and 12 to 15 months of age. The main difference between Groups 1 and 2 is that participants in Group 2 will have the first blood sample collected at an earlier time than those in Group 1. Once 400 participants have been assigned to Groups 1 and 2 then 100 new participants will be assigned to Group 3. Half the participants in Group 3 will receive PG4 in the second solution at 2, 4, 6, and 12 to 15 months of age. The other half of the participants in Groups 3 will receive 4 doses of 20vPnC (Prevnar 20®) at 2, 4, 6, and 12 to 15 months of age. Once the 100 participants have been assigned to Group 3 then 100 new participants will be assigned to Group 4. Half the participants in Group 4 will receive PG4 in the first solution at 2, 4, 6, and 12 to 15 months of age. The other half of the participants in Group 4 will receive 4 doses of a licensed pneumococcal comparator vaccine at 2, 4, 6, and 12 to 15 months of age. Participants will take part in this study for about 16 to 19 months (about 1 and a half years). During this time, participants will have 6 study clinic visits and 1 to 2 phone calls. At these study clinic visits, parent(s) or legal guardian(s) will be asked if the participant experienced any side effects. A side effect is an unintentional or unexpected reaction to a vaccine.
Conditions
- Pneumococcal Disease
Interventions
PG4Biological
Multivalent pneumococcal conjugate vaccine
20-valent pneumococcal conjugate vaccine (20vPnC)Biological
20-valent pneumococcal conjugate vaccine
15-valent pneumococcal conjugate vaccine (PCV15)Biological
15-valent pneumococcal conjugate vaccine
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants reporting local reactions within 7 days after each doseTime frame: Day 7
- Percentage of participants reporting systemic events within 7 days after each doseTime frame: Day 7
- Percentage of participants reporting adverse events (AEs)Time frame: Dose 1 to 1 month after Dose 3
- Percentage of participants reporting AEsTime frame: Dose 4 to 1 month after Dose 4
- Percentage of participants reporting serious adverse events (SAEs)Time frame: Dose 1 to 6 months after Dose 4
Locations
67 sites in 2 countries. Site status is shown where the registry gives one.
Northwest Arkansas Pediatric Clinic
Fayetteville, Arkansas
The Children's Clinic
Jonesboro, Arkansas
Los Ninos Children's Medical Clinic
La Puente, California
Los Ninos Children's Medical Clinic
West Covina, California
Velocity Clinical Research, Washington DC
Washington D.C., District of Columbia
Riveldi Biomedical Research and Associates - Miami
Miami Lakes, Florida
Clinical Research Prime
Idaho Falls, Idaho
The Iowa Clinic
Ankeny, Iowa
Cotton O'Neil Pediatrics
Topeka, Kansas
Kentucky Pediatric/ Adult Research
Bardstown, Kentucky
All Children Pediatrics
Louisville, Kentucky
Bluegrass Clinical Research, Inc.
Louisville, Kentucky
LSUHSC Clinical Trials Office
Shreveport, Louisiana
Louisiana State University Health Sciences Shreveport
Shreveport, Louisiana
Ochsner/LSU Health Ambulatory Care Center
Shreveport, Louisiana
University of Maryland
Baltimore, Maryland
UMB/CVD
Frederick, Maryland
Pediatric Associates of Fall River
Fall River, Massachusetts
Boeson Research GTF
Great Falls, Montana
OBGYN Associates
Great Falls, Montana
Origin Health
Great Falls, Montana
Boeson Research KAL
Kalispell, Montana
Heart and Hands Midwifery and Family Practice
Kalispell, Montana
POEM Healthcare
Kalispell, Montana
Blue Moose Pediatrics
Missoula, Montana
Boeson Research Laboratory
Missoula, Montana
Boeson Research MSO
Missoula, Montana
Midwest Children's Health Research Institute
Lincoln, Nebraska
Child Health Care Associates
East Syracuse, New York
University of Rochester
Rochester, New York
University of Rochester Medical Center
Rochester, New York
Velocity Clinical Research Inc.
Durham, North Carolina
Duke Vaccine and Trials Unit
Durham, North Carolina
Durham Pediatrics at North Duke Street
Durham, North Carolina
Dayton Clinical Research
Dayton, Ohio
Ohio Pediatric Research Assn.
Dayton, Ohio
Senders Pediatrics
South Euclid, Ohio
Cyn3rgy Research
Gresham, Oregon
Allegheny Health and Wellness Pavilion
Erie, Pennsylvania
Square-1 Clincal Research
Erie, Pennsylvania
Showing 40 of 67 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.